CR20150254A - Compuestos quimicos - Google Patents

Compuestos quimicos

Info

Publication number
CR20150254A
CR20150254A CR20150254A CR20150254A CR20150254A CR 20150254 A CR20150254 A CR 20150254A CR 20150254 A CR20150254 A CR 20150254A CR 20150254 A CR20150254 A CR 20150254A CR 20150254 A CR20150254 A CR 20150254A
Authority
CR
Costa Rica
Prior art keywords
chemical compounds
derivatives
imidazo
biphenyl
refers
Prior art date
Application number
CR20150254A
Other languages
English (en)
Inventor
Kiyoyuki Omoto
Robert Mckenzie Owen
David Cameron Pryde
Christine Anne Louise Watson
Mifune Takeuchi
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of CR20150254A publication Critical patent/CR20150254A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención se refiere a derivados de imidazopiridazina. Más en particular, se refiere a derivados de 4-(bifenil-3-il)-7H-imidazo[4,5-c]piridazina de la Fórmula (I), y a sales de estos aceptables desde el punto de vista farmacéutico, en donde R1, R2, R3, R4 y R5 son como se definieron en la descripción.
CR20150254A 2012-12-14 2015-05-14 Compuestos quimicos CR20150254A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737157P 2012-12-14 2012-12-14
PCT/IB2013/060631 WO2014091368A1 (en) 2012-12-14 2013-12-04 Imidazopyridazine derivatives as gabaa receptor modulators

Publications (1)

Publication Number Publication Date
CR20150254A true CR20150254A (es) 2015-07-09

Family

ID=49880883

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150254A CR20150254A (es) 2012-12-14 2015-05-14 Compuestos quimicos

Country Status (44)

Country Link
US (3) US8952008B2 (es)
EP (1) EP2938615B1 (es)
JP (1) JP5869740B2 (es)
KR (1) KR101746314B1 (es)
CN (1) CN104837843B (es)
AP (1) AP2015008526A0 (es)
AR (1) AR093937A1 (es)
AU (1) AU2013356894B2 (es)
BR (1) BR112015014097B1 (es)
CA (1) CA2892174C (es)
CL (1) CL2015001652A1 (es)
CR (1) CR20150254A (es)
CU (1) CU24338B1 (es)
CY (1) CY1118568T1 (es)
DK (1) DK2938615T3 (es)
DO (1) DOP2015000147A (es)
EA (1) EA025635B1 (es)
EC (1) ECSP15029822A (es)
ES (1) ES2608640T3 (es)
GE (1) GEP201706710B (es)
GT (1) GT201500159A (es)
HK (1) HK1209743A1 (es)
HR (1) HRP20161559T1 (es)
HU (1) HUE032400T2 (es)
IL (1) IL239243A0 (es)
LT (1) LT2938615T (es)
MA (1) MA38112B1 (es)
MD (1) MD4651B1 (es)
ME (1) ME02566B (es)
MX (1) MX366023B (es)
NI (1) NI201500081A (es)
PE (1) PE20151163A1 (es)
PH (1) PH12015501293B1 (es)
PL (1) PL2938615T3 (es)
PT (1) PT2938615T (es)
RS (1) RS55307B1 (es)
SG (1) SG11201503735YA (es)
SI (1) SI2938615T1 (es)
TN (1) TN2015000261A1 (es)
TW (1) TWI478926B (es)
UA (1) UA112028C2 (es)
UY (1) UY35185A (es)
WO (1) WO2014091368A1 (es)
ZA (1) ZA201504226B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9802945B2 (en) * 2014-06-12 2017-10-31 Pfizer Limited Imidazopyridazine derivatives as modulators of the GABAA receptor activity
TR201909606T4 (tr) 2014-07-31 2019-07-22 Basf Se Pi̇razollari hazirlamak i̇çi̇n i̇şlem
KR20230145498A (ko) 2015-05-11 2023-10-17 바스프 에스이 4-아미노-피리다진의 제조 방법
EP3386983A1 (en) * 2015-12-10 2018-10-17 Pfizer Limited 4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain
JOP20190053A1 (ar) * 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
EA038510B1 (ru) * 2016-09-23 2021-09-08 Новартис Аг Индазольные соединения для применения при повреждениях сухожилий и/или связок
WO2018082964A1 (en) 2016-11-04 2018-05-11 Basf Se Process for the production of pyridazinyl-amides in a one-pot synthesis
KR20200003047A (ko) 2017-05-02 2020-01-08 바이엘 악티엔게젤샤프트 해충 방제제로서의 2-(헤트)아릴-치환된 축합된 비시클릭 헤테로시클릭 유도체
WO2018224989A1 (en) * 2017-06-06 2018-12-13 Urovant Sciences Gmbh Use of vibegron to treat overactive bladder
EP3796907A4 (en) * 2018-05-22 2021-11-03 Neurocycle Therapeutics, Inc. GABAA POSITIVE ALLOSTERIC MODULATING COMPOUNDS FOR THE TREATMENT OF PRURITUS AND / OR DERMATITIS
TW202214648A (zh) * 2019-01-07 2022-04-16 美商美國禮來大藥廠 Il-17a抑制劑
CN116693555A (zh) * 2022-02-25 2023-09-05 上海赛默罗生物科技有限公司 咪唑并哒嗪类衍生物、其制备方法、药物组合物和用途
CN117069725A (zh) * 2022-05-10 2023-11-17 上海赛默罗生物科技有限公司 咪唑并哒嗪取代苯环类衍生物、制备方法、药物组合物及用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
GB0117277D0 (en) 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents
AU2002212530B2 (en) 2000-11-10 2006-08-17 Merck Sharp & Dohme Limited Imidazo-triazine derivatives as ligands for GABA receptors
WO2005080355A1 (en) * 2004-02-12 2005-09-01 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
WO2006078891A2 (en) 2005-01-21 2006-07-27 Neurogen Corporation Imidazolylmethyl and pyrazolylmethyl heteroaryl derivatives
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
CL2008000835A1 (es) 2007-03-23 2008-10-03 Icagen Inc Pfizer Ltd Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm
HUE025013T2 (hu) 2009-01-12 2016-04-28 Pfizer Ltd Szulfonamid-származékok
MX2012004990A (es) * 2009-10-30 2012-06-12 Janssen Pharmaceutica Nv Deribados de imidazo [1,2-b] pirimideazina y su uso como inhibidores de la enzima fosfodiesterasa 10.
WO2012004714A2 (en) * 2010-07-09 2012-01-12 Pfizer Limited Chemical compounds

Also Published As

Publication number Publication date
ME02566B (me) 2017-02-20
MX2015007598A (es) 2015-10-22
WO2014091368A1 (en) 2014-06-19
DK2938615T3 (da) 2017-01-02
CU24338B1 (es) 2018-04-03
MA38112A1 (fr) 2018-03-30
HRP20161559T1 (hr) 2016-12-30
CU20150058A7 (es) 2015-11-27
MA38112B1 (fr) 2018-10-31
MX366023B (es) 2019-06-24
MD20150051A2 (ro) 2015-09-30
SI2938615T1 (sl) 2017-02-28
BR112015014097A2 (pt) 2019-12-17
EP2938615B1 (en) 2016-10-26
IL239243A0 (en) 2015-07-30
US8952008B2 (en) 2015-02-10
CN104837843B (zh) 2016-08-31
ES2608640T3 (es) 2017-04-12
HK1209743A1 (zh) 2016-04-08
AU2013356894A1 (en) 2015-05-28
UA112028C2 (uk) 2016-07-11
HUE032400T2 (hu) 2017-09-28
DOP2015000147A (es) 2015-09-15
EA025635B1 (ru) 2017-01-30
RS55307B1 (sr) 2017-03-31
CN104837843A (zh) 2015-08-12
MD4651B1 (ro) 2019-09-30
CA2892174C (en) 2018-02-06
TW201434840A (zh) 2014-09-16
US20140171435A1 (en) 2014-06-19
TWI478926B (zh) 2015-04-01
SG11201503735YA (en) 2015-07-30
UY35185A (es) 2014-07-31
PE20151163A1 (es) 2015-08-14
AU2013356894B2 (en) 2015-11-12
KR101746314B1 (ko) 2017-06-12
NI201500081A (es) 2015-09-16
GT201500159A (es) 2015-09-23
ZA201504226B (en) 2016-06-29
EP2938615A1 (en) 2015-11-04
PL2938615T3 (pl) 2017-04-28
CA2892174A1 (en) 2014-06-19
ECSP15029822A (es) 2017-08-31
AR093937A1 (es) 2015-07-01
PH12015501293A1 (en) 2015-08-24
CL2015001652A1 (es) 2015-08-14
LT2938615T (lt) 2016-12-27
TN2015000261A1 (fr) 2016-10-03
BR112015014097B1 (pt) 2022-11-29
CY1118568T1 (el) 2017-07-12
US20150259352A1 (en) 2015-09-17
PH12015501293B1 (en) 2015-08-24
EA201590761A1 (ru) 2015-12-30
JP5869740B2 (ja) 2016-02-24
AP2015008526A0 (en) 2015-06-30
JP2016503001A (ja) 2016-02-01
KR20150088877A (ko) 2015-08-03
US20150105396A1 (en) 2015-04-16
GEP201706710B (en) 2017-07-25
PT2938615T (pt) 2016-12-26

Similar Documents

Publication Publication Date Title
CR20150254A (es) Compuestos quimicos
MX2019009100A (es) Nuevos derivados de triazolo[4,5-d]pirimidina.
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
UY33227A (es) Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
MX351812B (es) Derivados de piridona.
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
PE20150666A1 (es) Inhibidores de serina/treonina cinasa
CR20140132A (es) Derivados de pirrolopirimidina y purina
UA111640C2 (uk) ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
CY1116984T1 (el) ΠΑΡΑΓΩΓΑ [1,2,3]ΤΡΙΑΖΟΛΟ[4,5-d]ΠΥΡΙΜΙΔΙΝΗΣ ΩΣ ΑΓΩΝΙΣΤΕΣ ΥΠΟΔΟΧΕΑ ΚΑΝΝΑΒΙΝΟΕΙΔΩΝ 2
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
IN2015DN01035A (es)
UY35333A (es) Compuestos de azabencimidazol
UY33549A (es) Quinolil aminas como agentes inhibidores de las quinasas
UY35320A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA SUSTITUIDA CON HETEROARILO?.
CR20150171A (es) Benzamidas
DOP2015000060A (es) Profármacos de aminoquinazolina inhibidora de cinasa
PE20151145A1 (es) Piridopirazinas sustituidas como inhibidores de syk
EA201591939A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ АГОНИСТОВ РЕЦЕПТОРА CB2
UY32748A (es) 2-carboxamida-cicloamino-ureas
PH12015501146A1 (en) Hydantoin derivative
CU20110108A7 (es) [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos
UY32747A (es) 2-carboxamida-cicloamino-ureas sustituidas